Senores Pharmaceuticals Ltd

Financial Results

Senores Pharmaceuticals Q4 FY26 Results: Net Profit ₹36.7 Cr, Up 103.9% YoY

Senores Pharmaceuticals Ltd reported revenue from operations of ₹175.2 Cr (+53.4% YoY) and net profit of ₹36.7 Cr (+103.9% YoY) for Q4 FY26.

Key figure

Net profit ₹36.7 Cr · +103.9% YoY

Financial Results

Senores Pharmaceuticals Financial Results

Senores Pharmaceuticals reported audited FY26 consolidated total income of ₹679.89 Crore. The board also noted the resignation of the Company Secretary effective June 10, 2026.

Board Meeting Date

Senores Pharmaceuticals Board Meeting Date

Senores Pharmaceuticals scheduled a board meeting on May 14, 2026, to approve audited financial results. The trading window remains closed until 48 hours post-approval.

Debt & Borrowing

Senores Pharmaceuticals Debt & Borrowing: ₹54.07 Cr

Senores Pharmaceuticals Limited confirmed it does not meet the SEBI criteria for a 'Large Corporate' as of March 31, 2026. The company reported outstanding borrowings of ₹54.07 Crore for the period ended March 31, 2025. This disclosure is part of routine regulatory compliance regarding debt security issuance frameworks.

Value

₹54.07 Cr

Financial Results

Senores Pharmaceuticals Q3 FY26 Results: Net Profit ₹33.6 Cr, Up 104.9% YoY

Senores Pharmaceuticals Ltd reported net profit of ₹33.6 Cr (+104.9% YoY) for Q3 FY26.

Key figure

Net profit ₹33.6 Cr · +104.9% YoY